Ambassador George HARA

Group Chairman and CEO, DEFTA Partners;

Chairman of Board, Alliance Forum Foundation in Special Consultative Status with the UN Economic and Social Council;

Special Advisor to HKSTP;

Honorary Professor of Faculty of Medicine, CUHK

Mr. Albert WONG

Chief Executive Officer,

Hong Kong Science & Technology Parks Corporation

Dr. Grace Lau

Head of Institute for Translational Research,

Hong Kong Science & Technology Parks Corporation

Professor Kohji NISHIDA, M.D., Ph.D.

Director Premium Research Institute for Human Metaverse Medicine (PRIMe) in World Premier International Research Center Initiative (WPI),Osaka University;

Professor and Chairman of DepartmentOphthalmology Graduate School of Medicine, Osaka University

• Leader of Osaka University’s Premium Research Institute for Human Metaverse Medicine (PRIMe), a new science that integrates two academic fields: human organoid-based biomedical science and information and mathematical sciences.

 Talk title: Stem Cell Research and Regenerative Medicine for the Eye

Dr. Yu FUJITA, M.D., Ph.D.

Associate Professor, Division of Next-Generation Drug Development, Research Center for Medical Sciences, The Jikei University School of Medicine, Japan

• EV drug development research in Japan, aiming to pioneer first-in-class EV medicine. Co-founded EVerMed in 2024.
• Board member of The Japanese Society for Extracellular Vesicles (JSEV) and Board Member at Large of International Society for Extracellular Vesicles (ISEV).

Talk title: Extracellular Vesicle-Based Therapy for Regenerative Medicine

Professor Chi-Ying F. HUANG, Ph.D.

Distinguished Professor, Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University (NYCU)

• Exosome platform technology for transporting specific collections of effector molecules like mRNA and miRNA.
• Scope of applications: anti-cancer therapies, interventions for rare diseases, anti-aging, osteoarthritis and regeneration.

Talk title: Application of extracellular vesicles in biomedical research and disease treatment

Professor Wei ZUO, Ph.D.

Tenured Professor, Tongji University;

Deputy Director, Tongji Stem Cell Center;

Founder, Regend Therapeutics,Ltd;

Vice President, the Chinese Cell and Gene Therapy Society

• Has a spin-off company named “Regend Therapeutics Co., Ltd”, and his groundbreaking work includes the development of the world's first class of lung progenitor cell drug, REGEND001 (approval from China’s NMPA for Phase II clinical trials).

Talk title: Repair human lung and kidney using epithelial stem/progenitor cells: Curing the uncurable

Professor YUNG Shu Hang, Patrick, MH, JP

Associate Dean, Faculty of Medicine, CUHK;

Chairman, Department of Orthopaedics and Traumatology, Faculty of Medicine, CUHK;

Director, Centre of Neuromusculoskeletal Regenerative Medicine (CNRM)

• Director of Centre of Neuromusculoskeletal Regenerative Medicine (CNRM) of InnoHK cluster research centers.
• World recognized leader in the field of orthopaedic sports medicine, with contributions to arthroscopy and the advancement of regenerative therapies in orthopaedics and traumatology.

Talk title: Translational work in Orthopaedics Sports Medicine, where is the need?

Dr. dr. Karina, SpBP-RE

CEO of HayandraLab;

Staff faculty at Faculty of Medicine, UPN Veteran Jakarta

• Plastic surgeon at Hayandra Clinic in Jakarta, focus on adipose Stromal Vascular Fraction (SVF) (with patented H-Remedy SVF processing technique), Autologous Activated Platelet-Rich Plasma and immune cell therapy.

 Talk title: Regenerative Stromal Vascular Fraction: What We Learn from More Than 2,000 Cases in Indonesia.

Mr. Kunio Yamada 

Chairman & CEO, ROHTO Pharmaceutical Co., Ltd.